Sp5 Jun 2026 14:00
What is going on here, with a market cap now below $2b and $1.3b of net cash leaving an EV of around $600-700m for a business running above or near to cash breakeven seems much too low. For sure there are negatives. a less than convincing growth story, no permanent CEO, Orpathys seemingly not responding to Sachi approval, Sovleplenib approval deferral etc but there are enough positives to warrant a higher value than this.